

# Ulcerative Colitis - Pipeline Review, H1 2020

<https://marketpublishers.com/r/U44188EFA0EEN.html>

Date: April 2020

Pages: 671

Price: US\$ 2,000.00 (Single User License)

ID: U44188EFA0EEN

## Abstracts

Ulcerative Colitis - Pipeline Review, H1 2020

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ulcerative Colitis - Pipeline Review, H1 2020, provides an overview of the Ulcerative Colitis (Gastrointestinal) pipeline landscape.

Ulcerative Colitis (Colitis ulcerosa or UC) is a chronic disease mainly of the large intestine or colon and a type of Inflammatory Bowel Disease (IBD). The disease is characterized by open sores and ulcers in the colon. The risk factors for UC include smoking, family history of the disease, liver disease, colon cancer, depression, and severe dehydration. Common symptoms of ulcerative colitis include rectal bleeding, abdominal pain, and diarrhea. Treatment options for ulcerative colitis include surgery (removal of colon) or drug therapy with aminoasylates (ASA), immunomodulators, and corticosteroids.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ulcerative Colitis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Ulcerative Colitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ulcerative Colitis (Gastrointestinal) pipeline guide also reviews of key players

involved in therapeutic development for Ulcerative Colitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 4, 19, 53, 32, 2, 76 and 14 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 12 molecules, respectively.

Ulcerative Colitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Ulcerative Colitis (Gastrointestinal).

The pipeline guide reviews pipeline therapeutics for Ulcerative Colitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Ulcerative Colitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Ulcerative Colitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Ulcerative Colitis (Gastrointestinal)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Ulcerative Colitis (Gastrointestinal).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Ulcerative Colitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



## Contents

Introduction

Ulcerative Colitis - Overview

Ulcerative Colitis - Therapeutics Development

Ulcerative Colitis - Therapeutics Assessment

Ulcerative Colitis - Companies Involved in Therapeutics Development

Ulcerative Colitis - Drug Profiles

Ulcerative Colitis - Dormant Projects

Ulcerative Colitis - Discontinued Products

Ulcerative Colitis - Product Development Milestones

Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Ulcerative Colitis, H1 2020  
Number of Products under Development by Companies, H1 2020  
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020  
Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020  
Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020  
Number of Products under Development by Companies, H1 2020 (Contd..4), H1 2020  
Number of Products under Development by Companies, H1 2020 (Contd..5), H1 2020  
Number of Products under Development by Companies, H1 2020 (Contd..6), H1 2020  
Number of Products under Development by Companies, H1 2020 (Contd..7), H1 2020  
Number of Products under Development by Universities/Institutes, H1 2020  
Products under Development by Companies, H1 2020  
Products under Development by Universities/Institutes, H1 2020  
Number of Products by Stage and Target, H1 2020  
Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020  
Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020  
Number of Products by Stage and Target, H1 2020 (Contd..3), H1 2020  
Number of Products by Stage and Mechanism of Action, H1 2020  
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020  
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020  
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..3), H1 2020  
Number of Products by Stage and Route of Administration, H1 2020  
Number of Products by Stage and Molecule Type, H1 2020  
Ulcerative Colitis - Pipeline by 4D Pharma Plc, H1 2020  
Ulcerative Colitis - Pipeline by AbbVie Inc, H1 2020  
Ulcerative Colitis - Pipeline by AbGenomics International Inc, H1 2020  
Ulcerative Colitis - Pipeline by Abivax SA, H1 2020  
Ulcerative Colitis - Pipeline by Aclaris Therapeutics Inc, H1 2020  
Ulcerative Colitis - Pipeline by Affilogic SAS, H1 2020  
Ulcerative Colitis - Pipeline by Akebia Therapeutics Inc, H1 2020  
Ulcerative Colitis - Pipeline by Akeso Biopharma Inc, H1 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Ulcerative Colitis, H1 2020  
Number of Products under Development by Companies, H1 2020  
Number of Products by Top 10 Targets, H1 2020  
Number of Products by Stage and Top 10 Targets, H1 2020  
Number of Products by Top 10 Mechanism of Actions, H1 2020  
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020  
Number of Products by Top 10 Routes of Administration, H1 2020  
Number of Products by Stage and Top 10 Routes of Administration, H1 2020  
Number of Products by Top 10 Molecule Types, H1 2020  
Number of Products by Stage and Top 10 Molecule Types, H1 2020

### COMPANIES MENTIONED

4D Pharma Plc  
AbbVie Inc  
AbGenomics International Inc  
Abivax SA  
Aclaris Therapeutics Inc  
Affilogic SAS  
Akebia Therapeutics Inc  
Akeso Biopharma Inc  
Algernon Pharmaceuticals Inc  
Alivio Therapeutics Inc  
Allergan Plc  
Alpha Cancer Technologies Inc  
Alvotech ehf  
Am-Pharma BV  
Amgen Inc  
Antibe Therapeutics Inc  
Apidel SA  
Applied Molecular Transport LLC  
Arena Pharmaceuticals Inc  
Artelo Biosciences Inc  
AsiaBiome  
Asta Pharmaceuticals Co Ltd

Atlantic Bio Sci LLC  
Atlantic Healthcare Plc  
Avexegen Therapeutics Inc  
Axim Biotechnologies Inc  
Bilix Co Ltd  
BioXpress Therapeutics SA  
Boehringer Ingelheim International GmbH  
Bridge Biotherapeutics Inc  
Bristol-Myers Squibb Co  
Cellix Bio Pvt Ltd  
Celltrion Inc  
Chain Biotechnology Ltd  
ChemoCentryx Inc  
Chong Kun Dang Pharmaceutical Corp  
Circle33 LLC  
Cloud Pharmaceuticals Inc  
Cosmo Pharmaceuticals NV  
Cristcot HCA LLC  
CrystalGenomics Inc  
Cureveda LLC  
Cytocom Inc  
Dadang & BIO Co Ltd  
DeNovX LLC  
Devonian Health Group Inc  
DM Bio Ltd  
DNX Biopharmaceuticals Inc  
Dr. August Wolff GmbH & Co KG Arzneimittel  
EA Pharma Co Ltd  
Eli Lilly and Co  
Enceladus Pharmaceuticals BV  
enGene Inc  
Exeliom Biosciences SAS  
F. Hoffmann-La Roche Ltd  
Ferring International Center SA  
Finch Therapeutics Group  
First Wave Bio Inc  
FYB202 GmbH & Co KG  
Galapagos NV  
Genentech Inc

Gilead Sciences Inc  
GlaxoSmithKline Plc  
GLW Pharma  
Gossamer Bio Inc  
Guangzhou Magpie Pharmaceutical Co Ltd  
Hefei Cosource Pharmaceutical Inc  
Holy Stone Healthcare Co Ltd  
Ichnos Sciences Inc  
Iltoo Pharma  
Immunix Inc  
Impetis Biosciences Ltd  
Inception Sciences Inc  
InDex Pharmaceuticals Holding AB  
Innovate Biopharmaceuticals Inc  
Innovation Pharmaceuticals Inc  
Innovent Biologics Inc  
Innovimmune Biotherapeutics Inc  
InSight Biopharmaceuticals Ltd  
Intact Therapeutics  
Intas Pharmaceuticals Ltd  
Intract Pharma Ltd  
Istesso Ltd  
Jiangsu Hengrui Medicine Co Ltd  
Johnson & Johnson  
Kaken Pharmaceutical Co Ltd  
Kalytera Therapeutics Inc  
Kintai Therapeutics Inc  
Koutif Therapeutics LLC  
Kyowa Kirin Co Ltd  
Landos Biopharma Inc  
LG Chem Ltd  
LIPID THERAPEUTICS GmbH  
LTT Bio-Pharma Co Ltd  
MAKScientific LLC  
Metacrine Inc  
Microbiotica Ltd  
Mitsubishi Tanabe Pharma Corp  
Morphic Holding Inc  
NeuClone Pty Ltd

Nichi-Iko Pharmaceutical Co Ltd  
Novartis AG  
Nubiyota LLC  
Numedii Inc  
Nyrada Inc  
Oncodesign SA  
Oncostellae SL  
OSE Immunotherapeutics  
Ovamed GmbH  
Palatin Technologies Inc  
Palo BioFarma SL  
Pandion Therapeutics Inc  
PanTheryx Inc  
Paradigm Biopharmaceuticals Ltd  
Pfizer Inc  
Pharmapraxis  
Pharmaxis Ltd  
PNB Vesper Life Science Pvt Ltd  
Praeventix LLC  
Protab Ltd  
Protagonist Therapeutics Inc  
Protalix BioTherapeutics Inc  
Provention Bio Inc  
Qu Biologics Inc  
Re-Pharm Ltd  
Rebiotix Inc  
Regentys Corp  
ReveraGen BioPharma Inc  
RhemaStem SRLS  
Salix Pharmaceuticals Ltd  
Saniona AB  
Sareum Holdings Plc  
Semorex Technologies Ltd  
Seres Therapeutics Inc  
Servatus Ltd  
Shaperon Inc  
Siam Bioscience Co Ltd  
StemRIM Inc  
sterna biologicals GmbH & Co KG

Sublimity Therapeutics HoldCo Ltd  
Suzhou Connect Biopharmaceuticals Ltd  
Swedish Orphan Biovitrum AB  
Synedgen Inc  
Synlogic Inc  
Takeda Pharmaceutical Co Ltd  
Tarus Therapeutics Inc  
TheraSource LLC  
Theravance Biopharma Inc  
Thetis Pharmaceuticals LLC  
Tianjin Hemay Pharmaceutical Co Ltd  
Tillotts Pharma AG  
TopiVert Ltd  
Torrent Pharmaceuticals Ltd  
Ventria Bioscience  
Vivreon Biosciences LLC  
Voronoi

## I would like to order

Product name: Ulcerative Colitis - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/U44188EFA0EEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/U44188EFA0EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970